# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
BMO Capital analyst Kostas Biliouris maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Outperform and maintains $15 pr...
Centessa Pharmaceuticals (NASDAQ:CNTA) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate...
Shares of Take-Two Interactive Software, Inc. (NASDAQ: TTWO) fell sharply during Friday’s session following third-quarter res...
U.S. stocks traded mixed, with the Nasdaq Composite gaining around 100 points on Friday. Shares of SPS Commerce, Inc. (NASDAQ...
Centessa Pharmaceuticals plc (NASDAQ:CNTA), today announced new data from an additional 52-weeks of continuous treatment from t...